0.136

-0.003 (-2.16%)
Range 0.133 - 0.140   (5.26%)
Open 0.139
Previous Close 0.139
Buy Price 0.134
Buy Volume 5
Sell Price 0.136
Sell Volume 1
Volume 130.3
Value 17,581
Remark
Measurement Type Value
EPS (SGD) -0.011
Trailing EPS (SGD) -0.002
NAV (SGD) 0.036
Cash In Hand (SGD) 0.021
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 5.154
Price / Cash In Hand 8.598
Issued & Paid-up Shares 751,190,000
Treasury Shares -
Market Cap (M) 138.219
Par Value (SGD) n.a.
Beta - 75 Days 0.744
R-Squared - 75 Days(%) 7.33
Beta - 500 Days 0.56
R-Squared - 500 Days(%) 1.07
ISIN Code SG1BD9000009
Under CPF Investment Scheme (CPFIS) No
Index Components FTSE ST Catalist Index
Delayed prices. Updated at 28 Sep 2022 17:16.
Data powered by

Upcoming Events

AGM

Meeting Date 14 Oct 2022
Meeting Time 10:00 AM
NUSS Kent Ridge Guild House, Inner Chamber, 9 Kent Ridge Drive, Singapore 119241.
Data powered by SGX.
View All Events

About IX Biopharma

iX Biopharma Ltd. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of therapies for the treatment of acute and breakthrough pain, and male erectile dysfunction. Its segments include Specialty Pharmaceutical and Chemical Analysis segments. The Specialty Pharmaceutical segment is engaged in the development, manufacturing and sale of pharmaceutical products. The Chemical Analysis segment is engaged in the provision of laboratory testing services. Its products are Wafermine, which is a sublingual ketamine oral wafer that contains the non-opioid drug for the management of moderate to severe pain; Bnox, which is a sublingual buprenorphine oral wafer that is developed as a formulation for moderate to severe pain; PheoniX, which is used for the treatment of male erectile dysfunction; WaferRest, which is used for the alleviation of jet lag and improving sleep quality, and Wafernyl, which is used for breakthrough cancer pain.

Loading Chart...